A 58-year-old woman with a 10-year history of rheumatoid arthritis presents with progressive joint destruction, morning stiffness lasting 2 hours, and elevated inflammatory markers (ESR 68 mm/h, CRP 12 mg/dL). She has not received any disease-modifying antirheumatic drug (DMARD) therapy. What is the drug of choice for initial disease-modifying therapy?

Explanation

## Rheumatoid Arthritis: First-Line DMARD Therapy ### Pathophysiology of RA Rheumatoid arthritis is a chronic, systemic autoimmune disease characterized by: - Th1/Th17-mediated synovial inflammation - TNF-α and IL-6 overproduction by activated macrophages and fibroblasts - Immune complex deposition and complement activation - Progressive cartilage and bone destruction if untreated ### First-Line DMARD: Methotrexate **Key Point:** Methotrexate is the gold standard first-line DMARD for rheumatoid arthritis. It is the anchor drug in combination therapy and is used in nearly all RA treatment regimens. **High-Yield:** Methotrexate mechanism in RA: - Inhibits dihydrofolate reductase → ↓ purine and pyrimidine synthesis - Reduces T-cell and B-cell proliferation - Decreases TNF-α, IL-6, and IL-8 production (anti-inflammatory effect) - Onset of action: 6–12 weeks - Peak effect: 3–6 months ### Dosing & Administration - **Starting dose:** 7.5–10 mg/week (oral or subcutaneous) - **Titration:** Increase by 2.5–5 mg/week every 4–8 weeks to target 15–25 mg/week - **Folic acid supplementation:** 1 mg daily (or 5 mg on non-methotrexate days) to reduce toxicity ### Efficacy & Outcomes - **ACR20 response:** ~50% at 12 weeks - **Remission/low disease activity:** Achievable in 40–50% when combined with biologics - **Joint damage prevention:** Methotrexate monotherapy slows radiological progression; combination therapy with biologics achieves remission in many patients ### Monitoring Requirements - **Baseline:** CBC, LFTs, renal function, hepatitis B/C serology, TB screening - **During therapy:** CBC and LFTs every 8–12 weeks - **Toxicity:** Hepatotoxicity (rare with modern dosing), myelosuppression, mucositis, teratogenicity (absolute contraindication in pregnancy) ### First-Line DMARD Comparison | Agent | Onset | Efficacy | Toxicity | Role | |-------|-------|----------|----------|------| | **Methotrexate** | 6–12 weeks | High | Moderate (hepatotoxicity, myelosuppression) | **Anchor drug, first-line** | | Sulfasalazine | 8–12 weeks | Moderate | GI upset, rash, hepatotoxicity | Alternative monotherapy; part of triple therapy | | Hydroxychloroquine | 8–12 weeks | Low–moderate | Well-tolerated; retinopathy (rare) | Mild RA; adjunct therapy | | Leflunomide | 4–8 weeks | High | Hepatotoxicity, teratogenicity | Alternative if methotrexate intolerant | **Clinical Pearl:** Biologic DMARDs (TNF-α inhibitors, IL-6 inhibitors, JAK inhibitors) are NOT first-line monotherapy. They are added to methotrexate in patients with inadequate response or used in combination regimens for rapid remission induction. ### Why Methotrexate is First-Line 1. **Proven efficacy:** Decades of clinical data; slows radiological progression 2. **Cost-effectiveness:** Inexpensive compared to biologics 3. **Anchor drug:** Used in combination with all other DMARDs and biologics 4. **Tolerability:** Manageable toxicity profile with appropriate monitoring 5. **Guideline consensus:** ACR, EULAR, and Indian Rheumatology Association recommend methotrexate as first-line **Warning:** Corticosteroids (prednisolone) are NOT disease-modifying agents. They provide symptomatic relief but do NOT prevent joint destruction. They should be used as adjunctive therapy only, at the lowest effective dose, while waiting for DMARD onset. ### Treatment Algorithm ```mermaid flowchart TD A[Confirmed RA diagnosis]:::outcome --> B[Start Methotrexate]:::action B --> C{Response at 12 weeks?}:::decision C -->|Adequate response| D[Continue MTX monotherapy]:::action C -->|Inadequate response| E[Add biologic DMARD]:::action E --> F[TNF-α inhibitor + MTX]:::action F --> G{Remission/LDA?}:::decision G -->|Yes| H[Maintain combination therapy]:::action G -->|No| I[Switch biologic or add second agent]:::action ```